Evidence gap
The answer is genuinely unknown — a pending outcome trial will settle it.
Resolves via: Resolving-trial readout
Get this wrong and a generation of stroke-eligible AF patients trades a daily pill they could safely take for a permanent implant that may leave them more prone to stroke.
Active since Jun 2020
The debate
18 clinicians quoted on the record
Trials met noninferiority for the hard composite while cutting serious nonprocedural bleeding, so patients who hate or fear lifelong anticoagulation finally have a real alternative without waiting to fail pills first.
“This trial reframes left atrial appendage closure as a possible alternative to anticoagulation in selected patients, not just a bailout strategy.”
“may help expand use of LAAO in non-bleeding risk patients”
+ 1 more on this side
The numerically higher ischemic stroke signal, soft composite endpoints, and industry funding mean we can't yet call a one-time implant equal to a proven drug we can stop if something goes wrong.
“I’m not convinced that these devices should be considered an equal substitute for NOACs.”
Where the experts land
3–1 on record · 14 unplaced
Offer the device early · 3
On the record, unplaced · 14
Keep pills first-line · 1
“LAA occlusion remained noninferior to DOAC therapy in terms of the primary composite endpoint.”
Where the field stands
Common ground
Closure is a reasonable choice for AF patients who truly cannot take blood thinners.
The crux
Is less bleeding enough to offer a device as an equal first choice to patients who can take blood thinners, given conflicting trials and a possible rise in ischemic strokes?
Still unknown
Consistent long-term trial results showing closure matches blood thinners on ischemic stroke across broader patient groups would settle it.
On the record
Their own words — position stated as published
stay on OAC; LAAO not proven
“The results are clear: LAAC was worse than best medical therapy.”
John M. Mandrola · Electrophysiologist; Medscape/Sensible Medicine · 16 statements · Medscape ↗
high-risk patients not optimal for LAAO
“I think the result was indeed somewhat unexpected for us, because this is exactly the patient population where we are now doing left atrial appendage closure.”
Ulf Landmesser · Presenter · 6 statements · TCTMD ↗
LAAO is an option if wary of stopping OAC
“We really have to have a good conversation with them. We’ve all seen patients who have a CHA2DS2-VASc score of 0 and then a few months down the road they have a stroke.”
Oussama M. Wazni · Electrophysiologist · 5 statements · TCTMD ↗
trial does not reflect current devices/practice
“If you were to do the trial with current devices today, you would have very different results.”
Andrew Goldsweig · Chair · 2 statements · TCTMD ↗
Where do you land?
No votes yet — the measured split appears at 10.
Where the evidence stands
CLOSURE-AF failed noninferiority of catheter LAA closure versus physician-directed best medical care (mostly DOACs); the composite of stroke, embolism, major bleeding, or CV/unexplained death favored medical therapy. OPTION had previously supported LAAO after ablation. US/ESC guidelines still give LAAO a modest Class 2 recommendation. Mandrola called it a potential major reversal after >500,000 implants.
What's settled
4What's still open
4How this gets settled
The answer is genuinely unknown — a pending outcome trial will settle it.
Who could settle it
Know an expert who could settle this? Suggest one →
Who this affects
4.5M–7.5M
Who could fund or run it
Institutions that could fund, run, or adopt
Sources & verification
+ 71 more, each dated and verification-tagged
Who we found publicly on the record — a snapshot, not a poll of the field. Larger dots are deciders; dashed dots are scan-reported, not yet verified.